Beta-Peptide Lyotropic Liquid Crystals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The design of new lyotropic liquid crystals has been limited by the need for long poly-α-peptides, which are polydisperse and limited in sequence, making it difficult to systematically evaluate factors that modulate LC behavior and explore sequence-property correlations.
Innovation Solution
The use of short helical beta-peptides, which can form stable helices and self-assemble to create lyotropic liquid crystalline phases in aqueous environments, allowing for controlled sequence, composition, and length to probe relationships between beta-peptide structure and liquid crystallinity, enabling the formation of globally amphiphilic and non-amphiphilic lyotropic liquid crystals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long poly-α-peptides are used to form lyotropic liquid crystalline phases, then the liquid crystal phase can be formed, but the materials become polydisperse in size and limited in sequence, making it difficult to systematically evaluate factors that modulate LC behavior
Solution Approach 1:
The patent changes the fundamental parameter of peptide backbone structure from α-peptides to β-peptides. This parameter change enables the formation of liquid crystalline phases with shorter oligomers (reducing polydispersity) while maintaining the ability to form stable helical structures that self-assemble into LC phases. The β-peptide backbone provides enhanced conformational stability and predictable secondary structures, allowing for precise sequence control and systematic evaluation of structure-property relationships.
2Reliability
If polydisperse materials are used to form liquid crystal phases, then the liquid crystal phase can be formed, but the exploration of sequence-property correlations is hampered
Solution Approach 1:
The patent changes the peptide backbone from α to β configuration, which fundamentally alters the length requirement for LC phase formation. This parameter change enables the use of short, monodisperse β-peptide oligomers with precisely controlled sequences. The enhanced stability of β-peptide helices allows these short oligomers to self-assemble into liquid crystalline phases, thereby preserving sequence information and enabling systematic exploration of sequence-property correlations without the polydispersity problem.
3Manufacturing precision
If short oligomers are used, then the sequence control is improved, but the ability to form liquid crystal phases is reduced
Solution Approach 1:
The patent changes the backbone configuration from α to β, which fundamentally alters the conformational stability and self-assembly properties of the peptides. This parameter change enables short β-peptide oligomers to form stable helical structures that can self-assemble into liquid crystalline phases, thereby maintaining both short length (for sequence control) and LC phase formation capability.
Solution Approach 2:
The patent employs β-peptides with specifically designed side chains that create amphiphilic helical structures. These composite structures combine hydrophobic and hydrophilic regions, enabling the short oligomers to self-assemble into liquid crystalline phases in aqueous environments. The composite nature of these amphiphilic β-peptides allows them to overcome the length limitation while maintaining sequence control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the creation of lyotropic liquid crystals with tunable properties, such as viscosity and birefringence, suitable for applications like biomolecular sensing and chemical reaction templating, and provides a modular scaffold for tailoring LC mesogens for specific industrial applications.
Implementation Method 1
Beta-peptides have been shown to self-assemble in dilute solution and on gold surfaces
Implementation Method 2
globally amphiphilic beta-peptide, there is a surface dominated by lipophilic side chains running along one side of the helix, and a second surface dominated by hydrophilic side chains running along the opposing side
Implementation Method 3
lyotropic liquid crystalline phases that form in the presence of solvent
Implementation Method 4
these oligomers fold into compact and stable conformations that orient the side chains in predictable ways
Implementation Method 5
detecting the formation of the lyotropic liquid crystal wherein such formation identifies the candidate beta-peptide as capable of forming a lyotropic liquid crystal in an aqueous solvent
Data Source
AI summary
The present invention provides materials and methods that make liquid crystal phases accessible with relatively short β-peptides in aqueous solvents.